Sulfonylureas and glinides are usually avoided due to the risk of hypoglycemia, as are incretin-based therapies (DPP4 inhibitors and GLP-1 analogs) due to underlying pancreatic disease. This evidence concerns the gene DPP4 and Hypoglycemia.